A New Alzheimer’s Drug Comes With Lots Of Questions About How To Use It
(By Jon Hamilton for NPR) Nearly two months after the Alzheimer’s drug Aduhelm received conditional approval from the Food and Drug
Read More
Alzheimer’s/Dementia
Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign
(By Julie Appleby for Kaiser Health News) Do you sometimes lose your train of thought or feel a bit more
Read MoreUnitedHealth CEO: Unknowns of Biogen Alzheimer’s drug mean insurer won’t yet cover it
(By Nick Moran for Becker’s Hospital Review) UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on
Read MoreHow Might the FDA’s Approval of a New Alzheimer’s Drug Impact Medicaid?
(By Rachel Dolan and Elizabeth Williams for Kaiser Family Foundation published July 13, 2021) The recent approval of Aduhelm (aducanumab),
Read MoreCMS pushed to set national policy on Aduhelm access
(By Nick Moran for Becker’s Hospital Review) The Alzheimer’s Association joins insurers as the latest to call for CMS to
Read MoreWhy We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
(By Elisabeth Rosenthal for Kaiser Health News) The Food and Drug Administration’s approval in June of a drug purporting to
Read MoreDoctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug
(By Judith Graham for Kaiser Health News) As physicians and health policy experts debate the merits of Aduhelm, the first
Read MorePaying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
(By Judith Graham for Kaiser Health News) If you could invest $56 billion each year in improving health care for
Read MoreMedicare could limit who gets new Alzheimer’s drug
(By Lauren Jensik for Becker’s Hospital Review) Medicare members could face barriers to accessing Biogen’s new Alzheimer’s drug, Aduhelm, due to
Read MoreWill Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More